VENLAFAXINE BESYLATE
Clinical safety rating: caution
MAOIs can cause serotonin syndrome Can increase blood pressure and cause withdrawal symptoms upon discontinuation.
Venlafaxine and its active metabolite desvenlafaxine are potent inhibitors of neuronal serotonin and norepinephrine reuptake, and weak inhibitors of dopamine reuptake. It also has no significant affinity for muscarinic, histaminergic, or alpha-1 adrenergic receptors.
| Metabolism | Primarily metabolized by CYP2D6 to its active metabolite O-desmethylvenlafaxine (desvenlafaxine). Also metabolized by CYP3A4 to a lesser extent. |
| Excretion | Renal: 87% (5% unchanged venlafaxine, 29% unconjugated O-desmethylvenlafaxine, 26% conjugated O-desmethylvenlafaxine, 27% other metabolites). Fecal: minimal (<2%). |
| Half-life | Venlafaxine: 5 ± 2 hours; O-desmethylvenlafaxine (ODV): 11 ± 2 hours. Clinically, the effective half-life is prolonged in hepatic impairment (venlafaxine ~14 h) and severe renal impairment (venlafaxine ~10 h, ODV ~22 h). |
| Protein binding | Venlafaxine: 27% bound; O-desmethylvenlafaxine: 30% bound. Primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Venlafaxine: 7.5 L/kg (large, indicating extensive tissue distribution). Clinical meaning: high penetration into tissues, including brain. |
| Bioavailability | Oral immediate-release: 45% (due to first-pass metabolism); extended-release: comparable. Food does not affect bioavailability. |
| Onset of Action | Oral immediate-release: 1-2 weeks for antidepressant effect (maximal at 4-6 weeks); extended-release: 2-4 weeks. Anticholinergic-like effects may occur within hours. |
| Duration of Action | Immediate-release: dosed 2-3 times daily due to short half-life; extended-release: 24-hour dosing interval. Clinical benefit persists with continued dosing; withdrawal symptoms may occur if discontinued abruptly. |
For major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder: initially 37.5 mg po twice daily or 75 mg po once daily for 1 week; then increase to 75 mg po once daily; maximum 225 mg po once daily (immediate-release). For extended-release: 37.5-75 mg po once daily; maximum 225 mg po once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: reduce total daily dose by 25-50%. GFR <30 mL/min: reduce total daily dose by 50% and administer every other day if needed. Hemodialysis: administer dose after dialysis, reduce by 50%. |
| Liver impairment | Child-Pugh class A or B: reduce total daily dose by 50% (maximum 100 mg/day for immediate-release). Child-Pugh class C: use not recommended due to lack of data. |
| Pediatric use | Children ≥7 years for major depressive disorder: weight <40 kg, starting 37.5 mg po once daily for 1 week, then increase to 75 mg po once daily (extended-release); max 75 mg/day. Weight ≥40 kg: same as adult dosing up to 225 mg/day. Safety and efficacy not established for other indications. |
| Geriatric use | Elderly: use lower initial doses (e.g., 37.5 mg po once daily for extended-release); titrate slowly to minimum effective dose. Maximum dose 225 mg/day, but cautious use recommended. Monitor for hyponatremia and blood pressure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause serotonin syndrome Can increase blood pressure and cause withdrawal symptoms upon discontinuation.
| FDA category | Animal |
| Breastfeeding | Venlafaxine and its active metabolite O-desmethylvenlafaxine are excreted into breast milk. The milk-to-plasma (M/P) ratio for venlafaxine is approximately 2.5-3.5 and for its metabolite is higher, up to 4.7. The estimated relative infant dose is 5-10% of the maternal weight-adjusted dose. Case reports have noted infant serum levels near the limit of detection, with occasional adverse effects such as irritability, poor feeding, and sedation. The American Academy of Pediatrics considers venlafaxine compatible with breastfeeding, but caution is advised due to limited long-term data. Monitor infants for sedation, adequate weight gain, and developmental milestones. |
■ FDA Black Box Warning
WARNING: Suicidality and Antidepressant Drugs. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Monitor for worsening and emergence of suicidal thoughts and behaviors.
| Common Effects | anxiety disorders |
| Serious Effects |
["Concomitant use with MAOIs (including linezolid or IV methylene blue) due to risk of serotonin syndrome","Hypersensitivity to venlafaxine or any components"]
| Precautions | ["Clinical worsening and suicide risk (monitor closely)","Serotonin syndrome (especially with other serotonergic drugs)","Elevated blood pressure (dose-dependent)","Activation of mania/hypomania","Seizure risk (use cautiously in patients with seizure disorders)","Angle-closure glaucoma (may cause mydriasis)","Hyponatremia (SIADH risk, especially in elderly/dehydrated)","Abnormal bleeding (NSAIDs, aspirin use)","Interstitial lung disease and eosinophilic pneumonia (rare)","Sexual dysfunction","Discontinuation syndrome (taper dose gradually)"] |
Loading safety data…
| Teratogenic Risk | First trimester: Epidemiologic studies have not established a consistent association between venlafaxine use and major congenital malformations. However, some studies suggest a small increased risk of cardiovascular malformations (e.g., ventricular septal defects) with first-trimester exposure. Second and third trimesters: Exposure may increase risk for preterm birth, low birth weight, and neonatal adaptation syndrome (including irritability, feeding difficulties, respiratory distress, and seizures). Late third-trimester exposure is associated with persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation requiring prolonged hospitalization. Overall, the absolute risks are low, and the benefits of treating maternal depression may outweigh potential risks. |
| Fetal Monitoring | Maternal: Monitor for worsening depression, suicidal ideation, and serotonin syndrome (especially with concurrent serotonergic drugs). Assess blood pressure regularly due to dose-dependent hypertension. Monitor for signs of bleeding (venlafaxine may increase risk of postpartum hemorrhage). Fetal/neonatal: Monitor for neonatal adaptation syndrome (respiratory distress, feeding difficulties, jitteriness, seizures) for at least 48 hours after delivery. Consider ultrasound for fetal growth if exposure in second/third trimester. No specific fetal monitoring required solely due to venlafaxine exposure. |
| Fertility Effects | Animal studies have shown no impairment of fertility at clinically relevant doses. In humans, venlafaxine may cause sexual dysfunction (e.g., decreased libido, delayed ejaculation) which could affect fertility indirectly. There is no evidence of permanent effects on fertility. Discontinuation of venlafaxine may be considered in patients planning pregnancy, but risks of untreated depression should be weighed. |